Patients’ characteristics, tumor type and ICI treatments
| Baseline Characteristics | HIV (N = 21) | HBV/HCV (N = 34) |
|---|---|---|
| Age – Median (range) | 62 (29–85) | 62 (29–79) |
| Sex (% Male) | 52% | 71% |
| Race | ||
| (White %) | 33 | 25 |
| (African American %) | 67 | 50 |
| (Asian%) | 0 | 12 |
| Tumor types | ||
| Non-small cell lung cancer (NSCLC) | 12 | 10 |
| Adenocarcinoma | 8 | 5 |
| Squamous | 2 | 1 |
| Non specified | 2 | 4 |
| Anal squamous cell carcinoma | 2 | 2 |
| Hodgkin’s lymphoma (HD) | 2 | 0 |
| Head and neck squamous cell carcinoma (H&N) | 1 | 1 |
| Colorectal carcinoma (CRC) | 1 | 0 |
| Burkitt lymphoma | 1 | 0 |
| Renal clear cell carcinoma (RCC) | 1 | 3 |
| Hepatocellular carcinoma (HCC) | 1 | 16 |
| Small cell lung cancer (SCLC) | 0 | 1 |
| Gastric cancer | 0 | 1 |
| ICI therapy type | ||
| Anti-PD-(L)1 monotherapy | 16 | 30 |
| Anti-PD-(L)1 in combination with anti-CTLA-4 | 0 | 1 |
| Anti-PD-(L)1 in combination with chemotherapy | 5 | 3 |